Drugs / NeoCart
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00548119 | Dec 2006 → Nov 2009 | articular cartilage disorder | Histogenics Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01066702 | May 2010 → Mar 2019 | articular cartilage disorder | Histogenics Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NeoCart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00548119 ↗ |
| Modality | Cell therapy | “the NeoCart implant was safe when surgically applied as a cell-based therapy” PMID 28068480 ↗ Jan 2017 |